The video provides a technical analysis of the SPDR S&P Biotech ETF (XBI). Since August 12, 2025, the system ranked the ETF as hold or accumulate, with a score of 0. The ETF has gained nearly 10% since the initial recommendation, yielding an average return of 0.55% per day. The exchange-traded fund has broken through a strong upward trend. There is potential support at $94.01. According to fan theory, $100.33 is the next potential peak. The current 3-month trend indicates a potential 10.24% change, with a projected return ranging from 1.26% to 8.56%. A 12-month analysis indicates a projected change of -15.46%, with a potential range of -$44.59 to -$15.46. A stop-loss is set at $91.79. A general buy signal exist, however the open price are overvalued. This assessment has several positive signals but are downgraded.